|
|
 |
|
Viewing report
|
|
|
|
Breast Cancer Drug Futures 2010
Espicom Business Intelligence Ltd, Oct 2010, Pages: 307
Globally, breast cancer is the second most common cancer after lung cancer and the most common cancer for women. It is the second most common cause of death from cancer in women after lung cancer.
The breast cancer market is a steadily growing market due to effective treatments which have decreased mortality and resulted in a longer duration of therapy. The five-year survival rates for women with breast cancer have increased from under 70% 50 years ago to around 90% now.
Approximately 47% of breast cancer sales were derived from the US, with 41% Europe and 12% in Japan. Over the next six years the report forecasts that novel therapies including targeted monoclonal antibodies and small-molecule inhibitors, will increasingly be used in combination with chemotherapy and hormonal therapy.
NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER
This all new web service, Breast Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.
WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN:
- Track the drug’s progress and stay in-touch with developments
- Understand the drug’s novelty and mode of action
- Evaluate the strength of the company developing/producing the drug
- Review opportunities and challenges with the publishers unique 5-point competitive assessment
- Know the launch timeframe for new products or indications
- Be aware of promising mid-stage development candidates
- Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
- Review significant clinical trial results
STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS
For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include:
- Novelty/rationale for mechanism of action
- Current status
- Proof of concept/clinical data
- Development risks
- Company expertise
- Competition within the market-place
- Sales forecast (for key late-stage and launched products)
- Competitor ratio analysis score
- Clinical trial results
CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS
The Cancer Drug Futures Report incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon the analysts established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years’ of archive material.
Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to the Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.
With the Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Colorectal Cancer Drug Futures 2010
Lung Cancer Drug Futures 2010
Renal Cell Carcinoma Cancer Drug Futures 2010
Prostate Cancer Drug Futures 2010
Will Anyone Crack the Obesity Drug Market?
Cancer Drug Blockbusters to 2016
Multiple Sclerosis Drug Discoveries - What the Future Holds
Ophthalmology Drug Futures: Sight Preservation in Chronic Eye Diseases
MRSA Drug Futures
Threats to Avastin - Targeting the VEGF Pathway
|
|
|
|
